Dr. Kiran Avancha
CEO and co-founder, Prizm Therapeutics
Dr. Kiran Avancha has over 18+ years of strategic and business leadership experience in biotech, healthcare innovation, and clinical development. He is currently the inaugural Chief Innovation Officer for HonorHealth since 2022. Under his leadership, HonorHealth established an “Innovation Fund” that invested in about 16 companies and continues to grow its portfolio. He joined HonorHealth 8 years ago as the Chief Operations Officer of the Research Institute, where he led 3-fold revenue growth and built collaborations with over 300+ biotech, pharma, and life sciences companies. He is a serial entrepreneur, investor, mentor, and advisor for several health-tech and device startups.
As the CEO and co-founder of Prizm Therapeutics, a clinical-stage pediatric rare disease biotech, he is developing a novel therapy for treating MCT8 deficiency. MC8 deficiency is similar to cerebral palsy and is an X-linked genetic disorder impacting male children, with high unmet medical needs. He successfully launched and sold his first start-up, ClinSync Clinical Research, an Oncology CRO based out of India that is now operating in 6 countries.
Dr. Avancha is a licensed clinical pharmacist (RPh) and holds PhD in Medicinal Chemistry from the University of South Florida.